<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>311</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9753694</PubmedId>
            <Abstract>BACKGROUND: Vascular endothelial growth factor (VEGF) is a highly specific angiogenic growth factor; anti-angiogenic treatment through inhibition of receptor activation by VEGF might have important therapeutic applications in diseases such as diabetic retinopathy and cancer. A neutralizing anti-VEGF antibody shown to suppress tumor growth in an in vivo murine model has been used as the basis for production of a humanized version. RESULTS: Vascular endothelial growth factor (VEGF) is a highly specific angiogenic growth factor; anti-angiogenic treatment through inhibition of receptor activation by VEGF might have important therapeutic applications in diseases such as diabetic retinopathy and cancer. A neutralizing anti-VEGF antibody shown to suppress tumor growth in an in vivo murine model has been used as the basis for production of a humanized version.We present the crystal structure of the complex between VEGF and the Fab fragment of this humanized antibody, as well as a comprehensive alanine-scanning analysis of the contact residues on both sides of the interface. Although the VEGF residues critical for antibody binding are distinct from those important for high-affinity receptor binding, they occupy a common region on VEGF, demonstrating that the neutralizing effect of antibody binding results from steric blocking of VEGF-receptor interactions. Of the residues buried in the VEGF-Fab interface, only a small number are critical for high-affinity binding; the essential VEGF residues interact with those of the Fab fragment, generating a remarkable functional complementarity at the interface. CONCLUSIONS: Vascular endothelial growth factor (VEGF) is a highly specific angiogenic growth factor; anti-angiogenic treatment through inhibition of receptor activation by VEGF might have important therapeutic applications in diseases such as diabetic retinopathy and cancer. A neutralizing anti-VEGF antibody shown to suppress tumor growth in an in vivo murine model has been used as the basis for production of a humanized version.We present the crystal structure of the complex between VEGF and the Fab fragment of this humanized antibody, as well as a comprehensive alanine-scanning analysis of the contact residues on both sides of the interface. Although the VEGF residues critical for antibody binding are distinct from those important for high-affinity receptor binding, they occupy a common region on VEGF, demonstrating that the neutralizing effect of antibody binding results from steric blocking of VEGF-receptor interactions. Of the residues buried in the VEGF-Fab interface, only a small number are critical for high-affinity binding; the essential VEGF residues interact with those of the Fab fragment, generating a remarkable functional complementarity at the interface.Our findings suggest that the character of antigen-antibody interfaces is similar to that of other protein-protein interfaces, such as ligand-receptor interactions; in the case of VEGF, the principal difference is that the residues essential for binding to the Fab fragment are concentrated in one continuous segment of polypeptide chain, whereas those essential for binding to the receptor are distributed over four different segments and span across the dimer interface.</Abstract>
            <ArticleYear>1998</ArticleYear>
            <ArticlePages>1153-67</ArticlePages>
            <ArticleTitle>VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Muller</LastName>
                    <ForeName>Y A</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Y</ForeName>
                </Author>
                <Author>
                    <LastName>Christinger</LastName>
                    <ForeName>H W</ForeName>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>B</ForeName>
                </Author>
                <Author>
                    <LastName>Cunningham</LastName>
                    <ForeName>B C</ForeName>
                </Author>
                <Author>
                    <LastName>Lowman</LastName>
                    <ForeName>H B</ForeName>
                </Author>
                <Author>
                    <LastName>de Vos</LastName>
                    <ForeName>A M</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Protein Engineering Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antigen-Antibody Complex;Endothelial Growth Factors;Immunoglobulin Fab Fragments;Lymphokines;Vascular Endothelial Growth Factor A;Vascular Endothelial Growth Factors;Alanine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Alanine(chemistry); Amino Acid Sequence; Amino Acid Substitution; Antibodies, Monoclonal(chemistry; metabolism); Antigen-Antibody Complex(chemistry; genetics; immunology); Crystallography, X-Ray; DNA Mutational Analysis; Dimerization; Endothelial Growth Factors(chemistry; genetics; immunology); Epitope Mapping; Humans; Immunoglobulin Fab Fragments(chemistry; genetics; immunology); Lymphokines(chemistry; genetics; immunology); Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Binding; Protein Conformation; Protein Folding; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors</ArticleMeshHeadingsList>
            <Journal>
                <Volume>6</Volume>
                <Issue>9</Issue>
                <Title>Structure (London, England : 1993)</Title>
                <Issn>1878-4186</Issn>
                <MedlineTa>Structure</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Fab-12 epitope on VEGF</EpitopeName>
                <EpitopeStructure>
                    <RegionOnMultiChainMolecule>
                        <ChemicalType>Region on multi-chain protein</ChemicalType>
                        <MoleculeName>VEGF</MoleculeName>
                        <DiscontinuousResidues>V: F43, Y47; W: Y71, K74, Q105, I106, M107, R108, I109, K110, H112, Q113, G114, Q115, H116, I117, G118, E119, M120</DiscontinuousResidues>
                        <Chain1>
                            <Molecule>
                                <GenBankId>P15692.2</GenBankId>
                            </Molecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </Chain1>
                        <Chain2>
                            <Molecule>
                                <GenBankId>P15692.2</GenBankId>
                            </Molecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </Chain2>
                    </RegionOnMultiChainMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 3</LocationOfData>
                <EpitopeId>122246</EpitopeId>
                <ReferenceRegion>V: F17, Y21; W: Y45, K48, Q79, I80, M81, R82, I83, K84, H86, Q87, G88, Q89, H90, I91, G92, E93, M94;</ReferenceRegion>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope is composed of residues located in both chains of the VEGF homodimer.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1557443</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 μg of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab-12 . Additional mutations were introduced in generating the humanized Fab phagemid Y0192.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>45</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>3.4</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>Affinity of the epitope-specific Fab phage for the VEGF binding domain was calculated from the dissociaton to association rate constant ratio.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab Y0192 (humanized mAb A4.6.1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VEGF binding domain (8–109)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1557447</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 μg of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab-12. Additional mutations were introduced in generating the humanized Fab phagemid Y0192.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>263</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>0.00014</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The dissociaton and association rate constants were determined by surface plasmon resonance for the epitope-specific Fab phage binding to VEGF.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab Y0192 (humanized mAb A4.6.1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VEGF binding domain (8–109)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>1557444</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 μg of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab-12. Additional mutations were introduced in generating the humanized Fab phagemid Y0192.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>262</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>41000.0</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The dissociaton and association rate constants were determined by surface plasmon resonance for the epitope-specific Fab phage binding to VEGF.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab Y0192 (humanized mAb A4.6.1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VEGF binding domain (8–109)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 1159 and Table 3</LocationOfData>
                        <BCellId>1557448</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 μg of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab-12.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>310</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>4.7</QuantitativeMeasurement>
                            <AssayComments>Critical residues for binding of the epitope-specific mAb were determined by alanine scanning. IC50 values for the wild type were compared to mutants of the VEGF binding domain epitope residues. Residues M107, R108, I109, G114, Q115, and G118 showed 22- to 107-fold decreases in affinity relative to the wild type. Smaller, but significant, decreases in binding of about 5–8 fold were found for mutations at positions K74, Q105, K110, E119 and M120.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Display Library</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab Y0192 (humanized mAb A4.6.1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1,  3, 5, Tables 1, 2, 3 and PBD 1BJ1</LocationOfData>
                        <BCellId>1511861</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <MultiChainMolecule>
                                            <ChemicalType>Multi-Chain protein</ChemicalType>
                                            <MoleculeName>VEGF</MoleculeName>
                                            <Chain1>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain1>
                                            <Chain2>
                                                <Molecule>
                                                    <GenBankId>P15692.2</GenBankId>
                                                </Molecule>
                                                <SourceOrganismId>9606</SourceOrganismId>
                                            </Chain2>
                                        </MultiChainMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VEGF 165</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>MLP+TDM</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Several doses of 10 μg of conjugate</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the parent monoclonal antibody mAb A4.6.1 was previously described in the reference: Kim et al. (1992) Growth Factors 7(1): 53-64. [PMID: 1380254]. The isoform of 165 aa (VEGF 165) was used for the immunizations. The mAb A4.6.1 was humanized to generate Fab-12 .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.4</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Fab 12 on VEGF was determined from the crystal structure of the complex, solved by molecular replacement. The asymmetric unit contains one VEGF binding domain homodimer and two Fab fragments bound to the symmetrical poles of the VEGF dimer. The authors believe that presence of the sulfate is a crystallization artifact.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab 12 (humanized mAb A4.6.1)</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Fab 12</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1BJ1_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1BJ1_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VEGF binding domain (8–109)</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <MultiChainMolecule>
                                        <ChemicalType>Multi-Chain protein</ChemicalType>
                                        <MoleculeName>VEGF</MoleculeName>
                                        <Chain1>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain1>
                                        <Chain2>
                                            <Molecule>
                                                <GenBankId>P15692.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </Chain2>
                                    </MultiChainMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1BJ1</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>VW</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Epitope and paratope are the same as in the structure [PDB: 1CZ8]. Antigen does not change conformation upon antibody binding according to comparison with unbound antigen [PDB: 1VPF]. Contacts are shown in Figure 3 and Table 2.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>V: F17, Y21; W: Y45, K48, Q79, I80, M81, R82, I83, K84, H86, Q87, G88, Q89, H90, I91, G92, E93, M94;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: T30:H1, N31:H1, Y32:H1, G33:H1, W50:H2, N52:H2, T53:H2, Y54:H2, T55:H2, T59:H2, Y99:H3, P100:H3, H101:H3, Y102:H3, Y103:H3, G104:H3, S105:H3, S106:H3, H107:H3, W108:H3; L: Y91:L3, S92:L3, T93:L3, V94:L3, W96:L3;</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>908.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>835.0</ContactAreaForAntibody>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>V: F17, Y21; W: Y45, K48, Q79, I80, M81, R82, I83, H86, Q87, G88, Q89, H90, I91, G92, E93, M94</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: T30, N31, Y32, G33, W50, N52, T53, Y54, T59, Y99, P100, H101, Y102, Y103, G104, S105, S106, W108, (SO4)232; L: V94, W96</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>900.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>841.5</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

